US.: +1-650-918-5898
UK.: +44-020-8133-4027
AUS.: +61-2-4786-0457
INDIA: +91-848-285-0837
The global pharmaceutical industry is undergoing a consolidation phase in order to combat price pressure, competition and patent cliffs. Innovation is of vital importance for steady growth of pharmaceutical companies. Pharmaceutical companies have been mainly dependent on a few blockbuster molecules. However,with rapid decline in research and development (R&D) productivity and non-conducive regulatory environment, companies need to find... View more
The global pharmaceutical industry is undergoing a consolidation phase in order to combat price pressure, competition and patent cliffs. Innovation is of vital importance for steady growth of pharmaceutical companies. Pharmaceutical companies have been mainly dependent on a few blockbuster molecules. However,with rapid decline in research and development (R&D) productivity and non-conducive regulatory environment, companies need to find different avenues of growth. The patent expiry of blockbuster drugs is expected to pave way for generics. Due to difference in genetic composition of varied individuals, innovation is becoming more complex.This is influencing players offering complementary products and services to collaborate for new product development.
There are four major factors that are impacting the value creation in pharmaceutical industry:
Demand for personalized medicines is increasing in order to ensure effective treatment of various diseases
Investments in R&D for oncology and NCDs are increasing globally in order to provide cost-effective solutions available to ailing patients.
Market Challenges
The industry is facing certain challenges such as patent cliff, cost pressure and regulatory uncertainties across the globe. This is hindering market growth to a certain extent. Moreover, regulatory authorities are becoming more stringent with the drug approval process. However, with respect to drugs for rare diseases, the FDA has offered a fast-track approval process. Moreover, demand for cost-effective treatment for chronic and non-communicable diseases such as diabetes, hypertension, thyroid disorder, obesity, and cancer is increasing. However, there is a dearth of strong products in the pipeline that offer better treatment option with fewer side effects. The fear of side effects and long-term treatment costs is encouraging patients to shift to alternative therapies.
Combating Challenges
Market players need to combat these challenges and keep their pace with the industry to sustain their market share. Mergers, acquisitions, and divestitures of products, companies or business division is a rapidly emerging trend in the market to combat prevalent challenges in the market.Companies are more focused in terms of therapy areas and hence, are divesting less focused therapy businesses. A good example is the swap deal between GSK and Novartis in 2015.
Moreover, pharmaceutical companies are investing in consumer health products,with increasing consumer’s health awareness and emerging trend of self-medication. These trends are encouraging pharmaceutical companies to enter the OTC market and leverage their brand equity among the doctors, chemists and consumers. Companies such as GlaxoSmithKline, Cipla, Pfizer, Merck, Sun Pharma, and Abbott have a focused division or subsidiary for consumer healthcare products and markets.
Moreover, to combat increasing cost pressure, companies are evolving their distribution channel. Establishing facilities or presence through collaboration in regional markets has helped companies meet local demand with reduced costs and delivery time. Emergence of e-pharmacy has resulted in creation of a separate team in the organization to service consumers ordering medicines online. Moreover, companies are connecting with consumers through social media, which helps improve brand visibility. The distribution channel has thus evolved significantly from the decade old channel consisting of only wholesalers and physical retail shops.
Patient-centricity
Patients are increasingly becoming well informed and organized, sometimes demanding for a particular product from prescribers. Therefore, companies need to be more patient-centric in their approach and provide quality care to consumers. Pharmaceutical companies are focusing on established direct to consumer distribution channels and establishing a more strong relationship with them. Moreover, companies are creating a good purchase experience for consumers through different offerings such as post-purchase medical services, engaging the patient through social media and events, and providing regular product alerts and refilling services.
Growth in Emerging Economies
The pharmaceutical industry is rapidly expanding in emerging economies such as Asia Pacific, Africa, and Latin America. These regions possess immense potential for growth of pharmaceutical companies, owing to inadequate access to medicines, growing population and increasing incidence of non-communicable diseases (NCDs). Besides, demand for contract research and manufacturing is also high in these regions. China and India are the largest emerging markets for CRO and CMO. Companies are highly dependent on China for API supply owing to low purchase cost. Overdependence on a single country can pose a challenge for the pharmaceuticals sector in the near future. Therefore, other emerging countries such as India, Brazil and South Africa are encouraging investments in their country. Besides, global companies are establishing their facilities in Asia Pacific, Middle East and Latin America regions to enable close monitoring and servicing of lucrative regional markets.
Conclusion
Pharmaceutical companies need to focus on an integrated, patient-centric, value-driven approach along with technology integration and strategic partnerships in order to capitalize on lucrative growth opportunities in the market. Major global players in the market include Pfizer Inc., Merck & Co., Inc., Bayer AG, GlaxoSmithKline plc., Sanofi, F. Hoffmann-La Roche AG, AstraZeneca plc. and Novartis AG.
There is a paradigm shift in process in the global pharmaceutical industry from product to a ‘Prodice’ (Product and Service) model, to offer affordable, accessible and quality care to patients.View less
Published Date : Nov 2024
Global chemotherapy market is estimated to be valued at USD 10.87 Bn in 2024 and is expected to exhibit a CAGR of 7.8% during the forecast period (2024-2031). Chemotherapy is a type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized ... View more
Published Date : Nov 2024
The global antibodies contract manufacturing market is estimated to be valued at USD 19.61 Bn in 2024 and is expected to reach USD 38.30 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 10% from 2024 to 2031. Antibodies are glycoproteins produced by B ce... View more
Published Date : Nov 2024
Global canine orthopedics market is estimated to be valued at USD 344.1 Mn in 2024 and is expected to reach USD 611.2 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 8.5% from 2024 to 2031. The global canine orthopedics market has been witnessing steady... View more
Published Date : Nov 2024
Global veterinary orthopedics market is estimated to be valued at USD 625.1 Mn in 2024 and is expected to reach USD 1,109.1 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 8.54% from 2024 to 2031.The global veterinary orthopedics market is projected to ... View more
Published Date : Nov 2024
Global plasmid purification market is estimated to be valued at USD 1.98 Bn in 2024 and is expected to exhibit a CAGR of 11.4% during the forecast period (2024-2031). Plasmid purification is a technique of isolating plasmid DNA from bacterial cells. Bacterial plasmids... View more
Published Date : Nov 2024
The global breast cancer brachytherapy market is estimated to be valued at USD 898.1 Mn in 2024 and is expected to reach USD 1,423.2 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.8% from 2024 to 2031. Breast cancer brachytherapy is a form of radiati... View more
Published Date : Nov 2024
Global cannabis technology market is estimated to be valued at USD 4.10 Bn in 2024 and is expected to reach USD 20.01 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 25.4% from 2024 to 2031. Increasing legalization of medical and recreational cannabis a... View more
Published Date : Nov 2024
The global neuralgia treatment market is estimated to be valued at USD 2.41 Bn in 2024 and is expected to reach USD 3.72 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.4% from 2024 to 2031.Neuralgia, also known as neuropathic pain, is a chronic pain ... View more
Published Date : Nov 2024
Global monkeypox (Mpox) diagnosis market is estimated to be valued at USD 1.97 Bn in 2024 and is expected to reach USD 2.62 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 4.2% from 2024 to 2031. Global monkeypox virus (MPXV) outbreak in 2022 highlighte... View more
Published Date : Nov 2024
Global fetal bovine serum market is estimated to be valued at USD 1.86 Bn in 2024 and is expected to exhibit a CAGR of 13.6% during the forecast period (2024-2031). Fetal bovine serum is an important cell culture media supplement used in scientific research and variou... View more
Published Date : Nov 2024
Global cancer monoclonal antibodies market is estimated to be valued at USD 96.68 Bn in 2024 and is expected to exhibit a CAGR of 15.4% during the forecast period (2024-2031). Cancer monoclonal antibodies are artificially created proteins that have the capability to i... View more
Published Date : Nov 2024
The inhaled nitric oxide market is estimated to be valued at USD 1.22 Bn in 2024 and is expected to reach USD 2.03 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 7.5% from 2024 to 2031. Inhaled nitric oxide (iNO) is a selective pulmonary vasodilator ap... View more
Published Date : Nov 2024
Global medical marijuana market is estimated to be valued at USD 22.34 Bn in 2024 and is expected to exhibit a CAGR of 14.1% during the forecast period (2024-2031). The medical marijuana market has witnessed significant growth in recent years owing to the increasing l... View more
Published Date : Nov 2024
Global vitamin B12 drops market is estimated to be valued at USD 141.5 Mn in 2024 and is expected to exhibit a CAGR of 7.8% during the forecast period (2024-2031). Vitamin B12 plays a key role in red blood cell formation, neurological function, and DNA synthesis. It h... View more
Published Date : Nov 2024
Global TCV vaccines market is estimated to be valued at USD 412.8 Mn in 2024 and is expected to exhibit a CAGR of 12.4% during the forecast period (2024-2031). The TCV vaccines market has been witnessing steady growth over the past few years due to increasing incidenc... View more
Published Date : Nov 2024
Global specialty injectable market is estimated to be valued at USD 56.92 Bn in 2024 and is expected to exhibit a CAGR of 9.8% during the forecast period (2024-2031). Specialty injectable refers to injectable drug therapies that are administered through sites such as ... View more
Published Date : Nov 2024
Global systemic scleroderma treatment market is estimated to be valued at USD 1.71 Bn in 2024 and is expected to exhibit a CAGR of 4.9% during the forecast period (2024-2031). Systemic scleroderma is a chronic autoimmune connective tissue disorder that causes hardenin... View more
Published Date : Nov 2024
Global vitamin and mineral supplement tablets market is estimated to be valued at USD 15.91 Bn in 2024, and is expected to exhibit a CAGR of 4.7% during the forecast period (2024-2031). Vitamin and mineral supplements are essential nutrients that bodies cannot produce... View more
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
860519526
9001:2015
27001:2022